Unichem Laboratories Limited

Unichem Laboratories Limited, established in 1944 by the late Mr. Amrut Mody, is a prominent Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in the manufacturing and marketing of pharmaceutical formulations across various therapeutic areas, including gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives, and pain management.

In August 1962, Unichem Laboratories Limited was incorporated as a public limited company under the Corporate Identification Number (CIN) L99999MH1962PLC012451. The company is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 506690 and on the National Stock Exchange (NSE) under the ticker symbol UNICHEMLAB.

As of March 2025, Unichem Laboratories reported a revenue of ₹1,472.55 crore and a net worth of ₹2,294.63 crore. The company employs approximately 3,635 professionals. In 2023, Ipca Laboratories Limited acquired a 52.67% stake in Unichem Laboratories, further strengthening its position in the pharmaceutical industry.

Unichem Laboratories operates multiple manufacturing facilities across India, strategically located to serve both domestic and international markets. The company's formulation manufacturing plants are situated in Goa, Ghaziabad (Uttar Pradesh), and Baddi (Himachal Pradesh), while its Active Pharmaceutical Ingredient (API) manufacturing units are located in Roha (Maharashtra), Pithampur (Madhya Pradesh), and Kolhapur (Maharashtra).

These facilities are designed to meet the stringent quality standards required for global markets. Several of Unichem's plants have received approvals from international regulatory bodies, including the US FDA, UK MHRA, ANVISA (Brazil), COFEPRIS (Mexico), PMDA (Japan), TGA (Australia), and EDQM (Europe).

The leadership team at Unichem Laboratories is headed by Managing Director Pabitrakumar Kalipada Bhattacharyya, who oversees the company's strategic direction and operations. Sanjay Jain serves as the Chief Financial Officer, responsible for managing the company's financial strategies and performance.

Other key executives include Pradeep Bhandari, Head of Legal, Company Secretary, and Compliance Officer; Dr. Dhananjay Sathe, Chief Scientific and Compliance Officer; Prasad Joshi, Vice President of Human Resources and Employee Relations; Vinod Kumar Behl, Head of Projects and Investments; Jalesh Burye, Chief Quality and Compliance Officer; Utkarsh Patil, Chief Manufacturing Officer of Formulations; and Bhagwat S. Dhingra, Chief Executive of Domestic Pharma.

Unichem Laboratories has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's formulation manufacturing facilities in Goa, Ghaziabad, and Baddi have received approvals from the US FDA, UK MHRA, and EDQM, facilitating access to these markets.

In the United States, Unichem has been proactive in obtaining Abbreviated New Drug Application (ANDA) approvals from the US FDA. For instance, in August 2020, the company received ANDA approval for Tolterodine Tartrate Tablets, and in July 2020, for Amiodarone Tablets. These approvals underscore Unichem's commitment to meeting the regulatory requirements of key international markets.

Unichem Laboratories has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facilities have been accredited by international organizations such as the WHO, enabling access to these regions. Additionally, Unichem has established subsidiaries in Brazil and South Africa, further strengthening its presence in Latin America and Africa.

Unichem Laboratories has strategically diversified its geographic presence to mitigate concentration risk and enhance market reach. The company's operations span across India, the United States, Europe, and emerging markets in Africa, Latin America, and Southeast Asia. This diversification allows Unichem to leverage growth opportunities in various regions while maintaining a balanced portfolio.

Unichem Laboratories has demonstrated a strong commitment to meeting the regulatory standards of the US market. The company's manufacturing facilities in Goa, Ghaziabad, and Pithampur have received approvals from the US FDA, indicating compliance with stringent quality and safety standards. Furthermore, Unichem has been proactive in obtaining ANDA approvals for its products, facilitating the introduction of generic formulations into the US market. For example, in August 2020, the company received ANDA approval for Tolterodine Tartrate Tablets.

Unichem Laboratories' manufacturing facilities have been accredited by the World Health Organization (WHO) and the European Directorate for the Quality of Medicines (EDQM). These certifications affirm the company's adherence to international quality standards, enhancing its credibility and facilitating access to global markets.

In India, Unichem Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with national regulatory requirements. The company's facilities have also received approvals from state drug controllers, further validating their adherence to local standards. Additionally, Unichem has obtained export No Objection Certificates (NOCs), enabling the export of its products to various international markets.

Unichem Laboratories has maintained a proactive approach to regulatory compliance, with no significant adverse actions reported in recent years. The company's facilities have consistently met the standards set by regulatory bodies such as the US FDA, WHO, and EDQM, reflecting its commitment to quality and safety.

In the pharmaceutical industry, Unichem Laboratories faces competition from both domestic and international companies. Key competitors include Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Divi's Laboratories Ltd, and Granules India Ltd. These companies operate in overlapping therapeutic categories and markets, contributing to a dynamic competitive environment.

Unichem Laboratories distinguishes itself through its backward integration into Active Pharmaceutical Ingredient (API) manufacturing, adding value to customers in terms of quality and sustainability. The company's commitment to research and development, exemplified by its Centre of Excellence at Goa, enables the development of novel drug delivery systems and biosimilars.

Unichem Laboratories is strategically positioned as a global pharmaceutical company with a focus on generics, specialty products, and biosimilars. The company's robust research and development capabilities, coupled with its international manufacturing facilities, support its strategic direction and future growth prospects.

Unichem Laboratories has demonstrated a consistent track record in manufacturing and exporting pharmaceutical formulations. The company's export volume and consistency are evidenced by its total export value of $241.0 million USD and 5,363 shipments across 19 products in 9 therapeutic categories. Reliability indicators include approvals from multiple international regulatory bodies and a diversified product portfolio.

Importers should verify the following certifications to ensure product quality and compliance:

• FDA Approval: Confirm the product's approval status through the US FDA's Orange Book.

• WHO-GMP: Check the World Health Organization's list of prequalified manufacturers.

• EU GMP: Review the European Medicines Agency's list of authorized manufacturers.

• ISO Certification: Obtain copies of ISO certificates directly from Unichem Laboratories.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm that the product has